Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

253
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
253
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

419
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
419
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.0K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.0K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.1K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

879
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
879
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

990
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
990

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The cost of efficiency in flexible neural representations.

bioRxiv : the preprint server for biology·2026
Same author

Regulation of histones in thromboinflammation.

Frontiers in immunology·2026
Same author

Estimation of seroconversion and vaccination impact against FMD in India during 2006-2022 using survey sampling and Bayesian approaches.

Scientific reports·2026
Same author

Trajectories of Response Inhibition Development in Adolescence.

bioRxiv : the preprint server for biology·2026
Same author

Prefrontal Mechanisms of Rule Learning.

bioRxiv : the preprint server for biology·2026
Same author

Physiological, Histological, and Cognitive Characterization of a Rhesus Macaque Model of Presbycusis.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Oct 26, 2025

Combined Invasive Subcortical and Non-invasive Surface Neurophysiological Recordings for the Assessment of Cognitive and Emotional Functions in Humans
08:25

Combined Invasive Subcortical and Non-invasive Surface Neurophysiological Recordings for the Assessment of Cognitive and Emotional Functions in Humans

Published on: May 19, 2016

10.9K

Cholinergic Deep Brain Stimulation for Memory and Cognitive Disorders.

Saravanan Subramaniam1, David T Blake2, Christos Constantinidis1,3,4,5

  • 1Department of Neurobiology & Anatomy, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Journal of Alzheimer'S Disease : JAD
|August 2, 2021
PubMed
Summary
This summary is machine-generated.

Deep brain stimulation (DBS) shows promise for Alzheimer's disease by modulating brain activity. Targeting the nucleus basalis of Meynert with specific stimulation patterns may improve cognitive function and slow neurodegeneration.

Keywords:
Acetylcholinebasal forebrainprefrontal cortexworking memory

More Related Videos

Transcranial Direct Current Stimulation tDCS for Memory Enhancement
10:37

Transcranial Direct Current Stimulation tDCS for Memory Enhancement

Published on: September 18, 2021

14.8K
Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
14:14

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Published on: August 12, 2018

9.0K

Related Experiment Videos

Last Updated: Oct 26, 2025

Combined Invasive Subcortical and Non-invasive Surface Neurophysiological Recordings for the Assessment of Cognitive and Emotional Functions in Humans
08:25

Combined Invasive Subcortical and Non-invasive Surface Neurophysiological Recordings for the Assessment of Cognitive and Emotional Functions in Humans

Published on: May 19, 2016

10.9K
Transcranial Direct Current Stimulation tDCS for Memory Enhancement
10:37

Transcranial Direct Current Stimulation tDCS for Memory Enhancement

Published on: September 18, 2021

14.8K
Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
14:14

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Published on: August 12, 2018

9.0K

Area of Science:

  • Neuroscience
  • Neurology
  • Biomedical Engineering

Background:

  • Alzheimer's disease and dementia cause significant cognitive impairment.
  • Deep brain stimulation (DBS) is a potential therapeutic approach for neurodegenerative diseases.
  • Targeting specific brain structures is crucial for effective DBS treatment.

Purpose of the Study:

  • To explore the potential of DBS for treating memory and cognitive decline in Alzheimer's disease.
  • To investigate the nucleus basalis of Meynert as a viable DBS target.
  • To determine optimal stimulation parameters for cognitive enhancement.

Main Methods:

  • Review of recent human clinical and animal model studies on DBS for cognitive impairment.
  • Analysis of stimulation targets including the Papez circuit, ventral internal capsule, and cholinergic forebrain.
  • Consideration of stimulation parameters (frequency, pattern) for cholinergic forebrain stimulation.

Main Results:

  • DBS of the nucleus basalis of Meynert may therapeutically modulate neuronal activity.
  • Potential benefits include enhanced cortical activity and amelioration of Alzheimer's neuropathology.
  • Lower stimulation frequencies or intermittent patterns may be more effective than high-frequency continuous stimulation.

Conclusions:

  • DBS targeting the nucleus basalis of Meynert offers a potential strategy for Alzheimer's disease.
  • Optimizing stimulation parameters is key for efficacy in cognitive enhancement.
  • While safety is supported by experience in movement disorders, long-term efficacy and tolerance require further investigation.